Bristol Myers Squibb (BMY) Q2 2026 (USD): Adj. EPS 2.04 (exp. 1.59), Revenue 12.97bln (exp. 11.75bln)

• FY revenue about 49-50bln (exp. 47.47bln).
• FY adj. EPS 6.75-7.00 (exp. 6.34).

Large-cap pharma beats on both lines and raises full-year guidance; the pattern for this cohort is that the guidance revision, not the quarter itself, sets the post-print tape. A beat accompanied by a raise in both revenue and EPS has historically produced a cleaner and more durable re-rating than a beat with unchanged outlook, since the market treats raised full-year ranges as confirmation that the driver is structural rather than a one-off item. The distinction that matters in the detail is where the beat sits: volume-driven strength in the core growth franchises tends to be rewarded, while beats carried by older products, favourable timing, or below-the-line adjustments are more often faded on the call. BMY's prior form is instructive here: the stock has historically traded heavily on pipeline and patent-cliff concerns, so beats that say little on the late-stage readouts and loss-of-exclusivity trajectory have tended to give back gains quickly, while those backed by pipeline updates have held them. The immediate follow-ons are the earnings call commentary on the drivers of the raise, any revision to patent-cliff assumptions, and whether the buy-side consensus tracks toward the new range or stays below it, which is usually the tell for how much of the move is sustainable.